Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

NCT05231122 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT05231122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05231122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2024
Completion date
March 15, 2027
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian clear cell adenocarcinoma, platinum-sensitive ovarian carcinoma, recurrent endometrial serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent fallopian tube serous adenocarcinoma, recurrent ovarian carcinoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian serous adenocarcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal clear cell adenocarcinoma, recurrent primary peritoneal endometrioid adenocarcinoma, recurrent primary peritoneal serous adenocarcinoma